Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

IPO Prophet® is a real-time IPO intelligence platform that gives investors a data-driven edge. Our team brings over 75 years of combined experience trading and investing in IPOs, translating firsthand market execution into proprietary quantitative analytics designed for today’s issuance environment.

Unlike traditional research providers that rely solely on commentary and retrospective analysis, IPO Prophet® is grounded in actual trading experience across multiple IPO cycles. Our platform integrates live market data, historical performance benchmarks, and predictive models to help investors evaluate deal quality, pricing discipline, demand strength, and post-IPO trading behavior as it unfolds.

From pre-deal analysis through pricing and aftermarket performance, IPO Prophet® delivers actionable, data-driven intelligence that helps investors make informed decisions at the moments that matter most.

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul><li>Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .</li><li>The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. </li><li>Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.</li></ul>

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics